A Phase 3 study evaluating bimekizumab for active psoriatic arthritis reached primary completion on May 25, 2026. The trial, identified as NCT04009499, enrolled 1131 participants to assess the long-term safety, tolerability, and efficacy of the drug in this patient population.
Background
The study investigated bimekizumab (Bimzelx), an intervention administered subcutaneously, in adult subjects diagnosed with active psoriatic arthritis (PsA). Psoriatic arthritis is a chronic inflammatory condition affecting joints and entheses, often associated with psoriasis. The trial's overarching objective was to thoroughly assess the long-term safety profile, sustained efficacy, and overall tolerability of bimekizumab as a treatment option for these patients.
Trial design
The completed Phase 3 study, registered under identifier NCT04009499, involved an enrollment of 1131 participants. All enrolled individuals were adult subjects suffering from active psoriatic arthritis. The intervention under investigation was bimekizumab, administered subcutaneously. The study was specifically designed to evaluate the long-term safety, long-term efficacy, and tolerability of this treatment, aiming to provide comprehensive data on its performance over an extended period in a substantial patient cohort.
What this means
The primary completion of this significant Phase 3 study for bimekizumab signifies the conclusion of the core data collection period for its primary objectives. This milestone is crucial for the development pathway of bimekizumab in treating psoriatic arthritis, as it indicates that all planned long-term assessments of safety, tolerability, and efficacy have been carried out. While the trial is now officially listed as completed, the detailed results, including specific outcome measurements and analyses, are not yet publicly available. Clinicians, researchers, and patient advocates will anticipate the publication of these comprehensive data to fully understand the long-term benefits and risks of bimekizumab, which will inform future treatment guidelines and patient management strategies for active psoriatic arthritis.
Source
The information regarding this trial's primary completion was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT04009499, titled "A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis", was updated to reflect primary completion on May 25, 2026 on clinicaltrials.gov.